Dr. Grunberg is a Managing Director at Longitude Capital. Prior to joining Longitude Capital in 2012, Dr. Grunberg was a Principal at Rho Ventures and an Engagement Manager at McKinsey & Company. Dr. Grunberg is a board-certified physician in Internal Medicine and completed his residency at Cornell’s New York Presbyterian Hospital. He has maintained a limited clinical practice in Internal Medicine and affiliations with UCSF and Kaiser Permanente.
Dr. Grunberg currently serves on the boards of 89bio (ETNB), Kala Pharmaceuticals (KALA) and WelbeHealth. He is also a board observer at Sydnexis. He previously served on the board of California Cryobank (acquired by GI Partners) and led Longitude’s investment in Practice Fusion (acquired by Allscripts). While at Rho Ventures he served on the board of AqueSys (acquired by Allergan) and was a board observer at both SARCode Bioscience (acquired by Shire) and PHT (acquired by ERT).
Dr. Grunberg holds an M.D. and an M.B.A from Duke University where he was a Fuqua Scholar and an A.B. in Economics and English from Amherst College.